Mark Allen, Andrew Fiorini, and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper.
Sergio and Alejandra explore emerging implantable neuromodulation therapies that are opening new possibilities in the rapidly evolving field.
Re-Vana Therapeutics enters collaboration with Cambridge Design Partnership on development of novel delivery system for OcuLief®, an in-situ forming implant for the sustained release of biologic ophthalmic formulations.
Steve Augustyn, our Deputy Head of Drug Delivery reflects on key themes for respiratory therapy
Karla Sanchez explores the rapidly evolving field of dementia care, examining both the current landscape and emerging technologies that empower patients to stay independent for longer.
Pace is accelerating for tackling neurodegenerative diseases. In this article, Biomedical Engineers Alejandra and Karla focus on two areas of progress: how treatments have moved on and hope for the future.
Therapeutic oligonucleotides are a promising therapy for future applications. Here, biomedical engineers, Alejandra and Carla, discuss the challenges that need to be addressed to unlock large-scale oligonucleotide manufacturing.
This paper explores the future of drug delivery systems, specifically at-home self-injection, and the way in which drugs will be packaged in the future to enhance patient experience and ensure successful clinical outcomes.
Fresh from 'Drug Delivery to the Lungs' conference in Edinburgh, Mark Allen shares his insights on the major themes from the event and a trend set to reshape the future of respiratory drug delivery.
With urgent and important demand for LFTs, jeopardizing performance, ease-of-use, supply chain availability, and low cost isn’t an option – but sustainability strategies are evolving in response to consumer expectations.
Ice cream and blood are two things you probably don’t want to think about simultaneously, but how a substance flows is a vitally important consideration for many products.
Senior Consultant Jon Powell shares some of the obstacles encountered conducting pilot builds in-house to help our clients bring devices to market – and gives four pointers for ideal pilot manufacturing for clinical trials.